热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 抗体 其他一抗

所有图片（1/6）

CPT1A Recombinant Rabbit mAb (S-1263-2)

Carnitine O-palmitoyltransferase 1(liver isoform),CPT1-L,Carnitine O-palmitoyltransferase I liver isoform (CPT I,CPTI-L),Carnitine palmitoyltransferase 1A,Succinyltransferase CPT1A

价格 ￥600.00 （ 供应商现货 ： 3-5个工作日）
货号 S0B0972
规格
数量
收藏 分享
产品介绍

产品介绍 FAQs 引用文献(1) 评论(0)

产品规格

  • 宿主来源

    Rabbit

  • 抗原名称

    CPT1A

  • 分子别名

    Carnitine O-palmitoyltransferase 1(liver isoform); CPT1-L; Carnitine O-palmitoyltransferase I liver isoform (CPT I; CPTI-L); Carnitine palmitoyltransferase 1A; Succinyltransferase CPT1A

  • 免疫原

    Recombinant Protein

  • 细胞定位

    Mitochondrion outer membrane

  • Accession

    P50416

  • 克隆号

    S-1263-2

  • 抗体类型

    Recombinant mAb

  • 抗体同种型

    IgG

  • 反应种属 ?

    Hu

  • 纯化方式

    Protein A

  • 浓度

    0.5 mg/ml

  • 标记

    Unconjugated

  • 性状

    Liquid

  • 缓冲体系

    PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300

  • 储存条件

    12 months from date of receipt / reconstitution, -20 °C as supplied

  • 应用

    IHC-P ?

    WB

    IP

  • 稀释度

    应用 稀释度
    WB 1:1000
    IP 1:50
    IHC-P 1:1000
背景介绍

  • CPT1A, or carnitine palmitoyltransferase 1A, is a crucial enzyme involved in the mitochondrial fatty acid oxidation (FAO) pathway, which is essential for energy homeostasis during fasting or prolonged exercise. It is responsible for the rate-limiting step of converting acyl-coenzyme as into acyl-carnitines, facilitating their transport into the mitochondria for oxidation. The regulation of CPT1A is complex and involves various genetic, epigenetic, physiological, and nutritional factors. In the context of cancer, CPT1A plays a significant role in tumor progression and metabolism. It has been found to be upregulated in various cancers, including lung cancer, and its increased expression is associated with poor prognosis. Targeting CPT1A has been proposed as a potential therapeutic strategy in cancer treatment. Inhibiting CPT1A can induce ferroptosis in cancer cells, including LCSCs, and enhance the efficacy of immune checkpoint therapy in lung cancer. Moreover, the combination of CPT1A inhibition with immunotherapy has shown synergistic effects in preclinical models, offering a new approach to overcome resistance to immunotherapy in lung cancer. Furthermore, CPT1A has been implicated in the metabolic reprogramming of cancer cells, promoting cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma. It also plays a role in conferring cancer cell resistance to immune-mediated cytolytic killing.

  • 免疫印迹

    • WB result of CPT1A Recombinant Rabbit mAb
      Primary antibody: CPT1A Recombinant Rabbit mAb at 1/1000 dilution
      Lane 1: HeLa whole cell lysate 20 µg
      Lane 2: MCF7 whole cell lysate 20 µg
      Lane 3: HepG2 whole cell lysate 20 µg
      Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
      Predicted MW: 88 kDa
      Observed MW: 90 kDa

  • 免疫沉淀

    • CPT1A Rabbit mAb at 1/50 dilution (1 µg) immunoprecipitating CPT1A in 0.4 mg HeLa whole cell lysate.
      Western blot was performed on the immunoprecipitate using CPT1A Rabbit mAb at 1/1000 dilution.
      Secondary antibody (HRP) for IP was used at 1/1000 dilution.
      Lane 1: HeLa whole cell lysate 20 µg (Input)
      Lane 2: CPT1A Rabbit mAb IP in HeLa whole cell lysate
      Lane 3: Rabbit monoclonal IgG IP in HeLa whole cell lysate
      Predicted MW: 88 kDa
      Observed MW: 90 kDa

  • 免疫组化

    • IHC shows positive staining in paraffin-embedded human kidney. Anti- CPT1A antibody was used at 1/1000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

    • IHC shows positive staining in paraffin-embedded human liver. Anti- CPT1A antibody was used at 1/1000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

    • IHC shows positive staining in paraffin-embedded human endometrial cancer. Anti- CPT1A antibody was used at 1/1000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

    • IHC shows positive staining in paraffin-embedded human hepatocellular carcinoma. Anti- CPT1A antibody was used at 1/1000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

FAQs

斯达特公司的抗体，可以回收利用几次？

我们一般不推荐客户回收利用抗体。 因为抗体使用之后缓冲体系已经发生改变，不同客户在回收抗体的保存条件上也会有差异，所以抗体回收使用效果无法保证。另外，我们对一批抗体回收验证测试，测试结果显示不同抗体可回收次数不同，一般效价越高的抗体，可重复使用的次数越多，客户可根据实验情况来确定

引用文献(1)

评论(0)